Skip to content
Head to head

ACADIA Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ACAD · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

ACAD -28.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
ACADVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price17.11515.02
Change today-2.73%-1.08%
1-year return-25.3%+22.0%
Market cap$2.96B$130.58B
52-week range15.86 – 30.96412.27 – 568.67
Valuation
P/E (TTM)8.0733.14
P/E percentile, own 5-yr range55th99th
P/B2.136.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)2.3015.32
Net profit (TTM)$397.51M$3.88B
Revenue (TTM)$1.20B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+22.8%+11.8%
Gross margin90.5%85.5%
Operating margin10.2%33.1%
Net margin30.1%30.7%
Free cash flow (TTM)$180.83M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership100.2%96.8%
Insider activity (12mo)35 buy / 15 sell28 buy / 22 sell
Short interest (% of float)4.8%1.9%
Analyst consensus77% buy / 23% hold (13)95% buy / 5% hold (21)
Analyst price target$32 (+86%)$624 (+21%)
StockVane view
StockVane Quant RatingD (17)C (68)
Company
Employees7986,400
Founded19931989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.